[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BioAtla, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100501390","phase-1-phase-1-study-evaluating-ba3182-in-patients-with-advanced-adenocarcinoma-100501390",false,"NCT05808634","Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.","An Open-label, Multicenter, Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Efficacy of BA3182, a Bispecific Epithelial Cell Adhesion Molecule (EpCAM)\u002FCD3 Antibody, in Patients With Advanced Adenocarcinoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma\n* Age ≥ 18 years\n* Adequate renal function\n* Adequate liver function\n* Adequate hematological function\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n* Patients must not have clinically significant cardiac disease.\n* Patients must not have known non-controlled CNS metastasis.\n* Patients must not have active autoimmune disease or a documented history of autoimmune disease.\n* Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.\n* Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.\n* Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and\u002For hepatitis C.\n* Patients must not be women who are pregnant or breast feeding.","ALL","18 Years",{"count":19,"type":20},168,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma",[26],"Advanced Adenocarcinoma",[28,29,30],"Advanced","Metastatic","Cancer","RECRUITING","2025-09-22",{"date":34,"type":35},"2025-09-25","ACTUAL",{"date":37,"type":35},"2023-07-14",{"date":39,"type":20},"2028-09-15",{"name":41,"class":42},"BioAtla, Inc.","INDUSTRY",9,""]